Solace, a healthcare startup launched in 2022, has secured a major victory in its latest funding round. The company raised a Series B investment led by Menlo Ventures, lifting its valuation to over $300 million. This funding marks a significant milestone in Solace’s journey to reshape how Medicare patients access healthcare guidance and advocacy.
Solace: Founded on a Vision of Personalized Care
When the founders of Solace launched the company, they identified a critical gap in the U.S. healthcare system. Millions of Medicare patients navigate complex diagnoses, fragmented treatment plans, and confusing insurance protocols without any structured support. Solace stepped in to fill this void.
The startup built its platform to guide Medicare beneficiaries through healthcare decisions with the help of trained advocates. These professionals don’t just answer questions—they stay by the patient’s side throughout their care journey. Solace equips patients to manage over 100 different conditions, offering them support via phone calls, digital check-ins, and in some cases, in-person help.
Unlike traditional telehealth services, Solace doesn’t rush through consultations. The company prioritizes long-term relationships between patients and care advocates. Each advocate understands the full medical history of the individual they support. They step in not just during hospital visits but also when patients need help understanding diagnoses, arranging transportation, or even organizing follow-up care.
What Makes Solace Different?
Solace doesn’t try to replace doctors. Instead, the platform works alongside medical professionals to create a more coordinated experience. The company partners with health plans, clinics, and primary care providers to plug the communication gaps that often cause patients to fall through the cracks.
Solace focuses on human connection. Instead of relying solely on chatbots or impersonal digital tools, it hires real people—licensed professionals—who get to know their clients. These advocates explain confusing medical terms in plain English. They help patients choose between treatment options. They ensure that someone follows up after appointments. In a healthcare environment that often feels cold and transactional, Solace delivers warmth and consistency.
The Impact: 100+ Conditions, Thousands of Lives
Solace started with a focus on seniors enrolled in Medicare. The company quickly realized that people with chronic conditions needed consistent, proactive support. Its care model now covers over 100 conditions, including diabetes, heart disease, Alzheimer’s, and cancer. Solace assigns care advocates who understand the unique progression of each illness and the emotional toll it takes on families.
Within two years, Solace expanded across several states and built relationships with major healthcare providers and insurers. It now supports tens of thousands of patients—and that number keeps climbing. The advocates under Solace’s umbrella don’t just react to problems; they prevent them. They follow up after ER visits. They schedule appointments before issues escalate. They even flag potential complications based on patient-reported symptoms.
This proactive approach doesn’t just help patients feel better—it also reduces costs for insurers. Fewer ER visits, fewer unnecessary procedures, and fewer readmissions lead to substantial savings. That win-win model attracted investors like Menlo Ventures, who saw both the business opportunity and the social impact.
Series B Funding: Fueling the Next Phase
The Series B round led by Menlo Ventures brings a fresh wave of capital, but also strategic support. Menlo, a Silicon Valley powerhouse, brings deep experience in scaling startups that blend human interaction with cutting-edge tech.
Solace will use this funding to scale operations across all 50 states. The company plans to triple its team of care advocates by the end of the year. It also intends to invest in its digital infrastructure—building smarter, AI-assisted tools that can flag red flags in patient behavior or remind advocates to follow up on specific health metrics.
The funding also unlocks expansion into new service areas. Solace wants to offer specialized support for mental health, dementia care, and end-of-life planning. These services require a sensitive, high-touch approach that aligns with the startup’s strengths. By building programs tailored to emotionally and medically complex cases, Solace aims to become indispensable to both patients and providers.
Investors Bet on the Human Touch
At a time when most startups race toward automation and AI, Solace leans into human connection. Investors believe this strategy offers a competitive edge. The company’s high customer satisfaction scores and low dropout rates prove that people trust Solace with their most personal health decisions.
“We invested in Solace because they understand what most health tech companies miss: real change starts with relationships,” said a partner at Menlo Ventures. “Solace combines empathy with data, and that makes them powerful.”
Other participants in the Series B include several healthcare-focused funds, early-stage investors, and repeat backers from Solace’s Series A round. This consistent show of faith demonstrates long-term confidence in the company’s business model and mission.
Challenges Ahead
Despite its growth, Solace faces several hurdles. The U.S. healthcare system remains complex, inconsistent, and slow to adopt new models. Convincing hospitals and health plans to integrate with an external support team takes time. Solace must continue proving that its services reduce costs and improve outcomes.
Recruiting enough skilled advocates also presents a challenge. The company plans to hire rapidly, but must maintain high standards to protect its reputation. Training, certification, and ongoing education remain key priorities as the team expands.
Privacy regulations add another layer of complexity. Solace handles sensitive medical data and must follow strict HIPAA compliance. As the company scales and builds more digital tools, it must ensure bulletproof security.
Finally, competition looms. As Solace proves the viability of its model, other startups may enter the market. Some may offer cheaper or more tech-heavy alternatives. Solace must stay focused on its value proposition: combining tech with empathy.
The Road Ahead
Solace doesn’t want to disrupt healthcare—it wants to rebuild trust in it. By focusing on people, not just systems, the startup has already made waves. With its new $300 million valuation and Series B funding, it stands poised to become a defining force in patient-centered care.
The team doesn’t plan to rest. Over the next 12 months, Solace will expand nationally, deepen partnerships with providers, and launch new programs aimed at underserved patient populations. Its founders believe that every person deserves an advocate who understands their health—and they intend to make that belief a reality for millions.
In a healthcare system often marked by confusion, isolation, and frustration, Solace brings clarity, support, and hope. With strong backing and a clear mission, the company looks ready to change the face of patient care in America—one conversation, one connection, and one life at a time.